RT Journal Article
T1 Editorial: Biomarkers of neurodegeneration and brain function and their relationships with clinical and neuropsychological outcomes in monitoring deep brain stimulation efficacy in movement disorder patients.
A1 Gonzalez-Rosa, Javier J
A1 Escamilla-Sevilla, Francisco
A1 Leocani, Letizia
K1 Parkinson's disease
K1 Biomarkers
K1 Deep brain stimulation
K1 Local field potentials
AB Deep brain stimulation (DBS) is a widely used therapy for a variety of movement disorders, such as Parkinson’s disease (PD), Essential Tremor (ET), and dystonia, mainly targeting the subthalamic nucleus (STN), thalamic ventral intermediate nucleus (Vim), and globus pallidus internus (Gpi). Although this treatment has been available for decades, studies on early- or long-term patient outcomes have been still limited. While DBS has evolved into an evidence-based standard treatment for movement disorders, the identification of preoperative or postoperative predicting factors in DBS candidates would be of imperative clinical value, allowing us to monitor surgical performance and improve surgical outcomes
PB Frontiers Research Foundation
SN 1664-2295
YR 2022
FD 2022-06-17
LK http://hdl.handle.net/10668/20646
UL http://hdl.handle.net/10668/20646
LA en
NO González-Rosa JJ, Escamilla-Sevilla F, Leocani L. Editorial: Biomarkers of neurodegeneration and brain function and their relationships with clinical and neuropsychological outcomes in monitoring deep brain stimulation efficacy in movement disorder patients. Front Neurol. 2022 Aug 3;13:936706
DS RISalud
RD Apr 8, 2025